Biotech Values

[DewDiligence]

The difficulty in gaining hospital sales as compared to retail, in my view, exists in the form of obtaining GPO contracts. While not all GPO contracts are with SNY enough of the big ones are so that if the figures mentioned today are strictly supplying wholesalers then it's not as bullish as it might seem on the surface. I wonder if there's any way to know how much of the wholesaler supply has trickled down to their hospital clients?

I would suggest that you are painting with too fine a brush. Wheeler said today that the commercial uptake of Lovenox in the two settings is similar, and this is consistent with what Sandoz itself said would happen on a webcast I heard two years ago (the one with the slide shown in #msg-53216579).

In other words, the commercial launch of generic Lovenox appears to be going according to plan. Until we get further color on NVS’ 3Q10 CC, that’s good enough for me.